Core Insights - Yuaneng Bio is actively preparing for its Series B financing and independent listing after completing a Series A financing of 410 million yuan in 2022 [1] - The company focuses on advanced automated low-temperature storage equipment for biological samples, addressing pain points in the biopharmaceutical industry [1] Group 1 - Yuaneng Bio was founded by Qu Jianguo, who has a history of successful entrepreneurial ventures, including transforming Shenhua Industry and founding Kaineng Health [1] - The company has developed a comprehensive product system that offers innovative solutions for various temperature ranges, sample types, and storage scales, including features like liquid nitrogen cold chain protection and remote management via 5G IoT [1] - As of December 2024, Yuaneng Bio has applied for over 600 domestic and international patents, with more than 500 granted [1] Group 2 - Yuaneng Bio's overseas brand, Orcella Instruments, won the "2025 Outstanding New Product Award" at the ISBER awards in Canada, recognized for its technical innovation, industry influence, data support, and market demand [2] - In March 2025, Yuaneng Bio was selected for the National "High-Quality Medical Devices Going Abroad Selection Guide (2025)" [2]